Patients with diabetes mellitus have an increased cardiovascular morbidity and mortality compared with the general population [1] . The development of diabetic vascular complications is a multifactorial process where altered lipoproteins, hyperinsulinaemia, hypertension and changes in blood rheology act in concert with hyperglycaemia to promote endothelial injury and accelerate the atherosclerotic process [2] . Thus, therapeutic advances leading to improved blood glucose control alone have proved disappointing in preventing the development and progression of macro-and microvascular complications associated with the disease [3] .
Omega-3 fatty acids are known to favourably influence many of the mechanisms involved in atherogenesis [4] and appear to reduce mortality from coronary heart disease [5, 6] and may therefore have therapeutic potential in preventing complications associated with diabetes mellitus. Recent evidence suggests dietary fish oils rich in eicosapentaenoic (20:5) and docosahexaenoic (22:6) fatty acids may prevent or delay diabetic complications attributable to microvascular disease [7] . While omega-3 fatty acids are recognised for their antiplatelet actions and effects on lipoprotein metabolism, there is increasing evidence that their vascular protective actions are expressed at the level of the vessel wall after incorporation into the phospholipids of cell membranes [8] . Dietary fish oil supplementation has been shown to improve endotheliumdependent relaxations to pharmacological stimulation in atherosclerotic porcine [9] and human [10] coronary vasculature. These improved vasodilator responses are mediated principally through the increased release of endothelium-derived relaxing factor [11, 12] now identified as [13] or an unstable nitroso compound related to NO [14] . Whether improved endothelinmmediated responses would occur from damaged endothelium in diabetic patients ingesting fish oils is unknown. This study was designed to investigate endotheliumdependent and independent responses to dietary fish oil and ofive oil supplementation in the forearm vasculature of patients with Type 2 (non-insulin-dependent) diabetes.
Patients and methods
Twenty male and three female patients with Type 2 diabetes whose ages ranged from 45-61 years were recruited for study. Diabetic control was achieved by diet alone or diet plus sulphonylurea or biguanide preparations or both. Patients were excluded from study if there was a history of cerebrovascular disease, ischaemic heart disease, or peripheral vascular disease, hypertension (blood pressure > 150/90), significant renal impairment (creatinine clearance < 30 ml/min) or if they were taking cardiovascular drugs. All patients underwent an extensive array of tests including retinal photography, ankle/arm Doppler ratios, cardiac autonomic function tests, biothesiometer measurements of vibration perception and urine collections for microalbuminuria and overt proteinuria as previously described, prior to entry into the study [15] . All participants gave written informed consent for all procedures. This study was approved by the local ethical committee of The Queen's University of Belfast.
Study design
Patients entered a double-blind placebo controlled study with random allocation of treatments consisting of three 6-week phases. During the first 6 weeks the patients received 10 capsules per day of fish oil (Maxepa; Duncan Flockhart, Greenford, Middlesex, UK) or identical appearing olive oil placebo capsules (preparations kindly provided by Duncan Flockhart) in a random fashion. Following a 6-week washout period, patients were allocated the capsules they had not previously received during the initial treatment phase for a final 6-week period. A 6-week treatment phase permitted sufficient time for incorporation of the fatty acids into the cell membranes. Fish oil capsules contained 18 % weight/weight eicosapentaenoic acid and 12 % docosahexaenoic acid to provide a daily intake of 1.8 g of eicosapentaenoic acid and 1.2 g of docosahexaemoic acid. The vitamin A content was less than 100 IU/g and the vitamin D content less than 10 IU/g. Patients adhered to their regular diets and medications throughout the study periods. Compliance with the medication was assessed by capsule counts on return of the bottle containers and by measurement of platelet membrane fatty acid composition by gas chromatography.
Protocol
Forearm blood flow was measured bilaterally by venous occlusion plethysmography during the initial baseline studies and on completion of each of the active treatment periods. Drug infusions were performed in the experimental forearm to determine the direct effect of the vasoactive drugs, while measurements in the control arm were monitored to ensure systemic effects did not occur during this period. Acetylcholine chloride (Miochol; Coopervision, Southampton, UK) was used to assess endothelium-dependent vasodilation, N~-monomethyl-L-arginine (L-NMMA), (Ultrafine Chemicals, Manchester, UK) was employed to inhibit basal and stimulated release of nitric oxide from the endothelium and glyceryl trinitrate (Nitrocine; Schwarz Pharma, Chesham, UK) was used as a smooth muscle vasodilator. A detailed description of the forearm blood flow and the vasoactive drug infusion protocols used during the initial baseline studies have been described previously [15] and were repeated in an identical fashion on completion of each active treatment period.
Venous blood was drawn from each subject after 30-rain supine rest during the baseline study and on completion of the active treatment phases for estimation of glycated haemoglobin, fasting glucose and for measurement of platelet fatty acids. An uncurled specimen was collected in EDTA tubes for estimation of the lipid and lipoprotein profiles by ultracentrifugation.
Statistical analysis
Forearm vasodilator responses to increasing doses of acetylcholine and glyceryl trinitrate in the diabetic subjects were analysed using the SPSS PC + package (SPSS Inc., Chicago, Ill., USA). Repeated measures analysis of variance was used to assess within-group and between-group responses for significant comparisons between doses. The relations between responses and baseline characteristics were examined using Dunnett's test. Comparisons between groups were assessed using paired t-tests. All data are reported as means and 95 % confidence intervals unless otherwise stated. A probability value of 0.05 or less was considered significant.
Results
Compliance with the fish oil and olive oil capsules was confirmed with bottle counts which suggested full consumption of the prescribed regimens. Assessment of platelet lipid fractions demonstrated the incorporation of both eicosapentaenoic acid and docosahexaenoic acid at the expense of arachidonic acid ( Table 1 ). The eicosapentaenoic acid/arachidonic acid ratio increased from 0.05 (confidence interval (CI): 0.04 to 0.06) at baseline to 0.15 (CI: 0.13 to 0.17) p < 0.001 with fish oil supplementation. Similar increases occurred in the docosahexaenoic acid/arachidonic acid ratio with fish oil therapy confirming significant consumption of the oils during the study period.
The haemodynamic and metabolic parameters recorded at the outset of the baseline study and after 6 weeks fish oil and olive oil administration are summarized in Table 2 . No significant changes occurred in mean arterial pressure, heart rate, basal forearm blood flow or basal forearm vascular resistance with fish oil or olive oil supplementation when compared to baseline values. The mean fasting blood glucose increased from a mmol/1 = mg/dl x 0.026; b mmol/l = mg/dl x 0.0114. Values expressed are means and 95 % confidence intervals baseline with fish oil administration though the change just failed to reach statistical significance (p = 0.06). A reduction in fasting triglyceride levels occurred with fish oil therapy when compared with baseline values though the trend was not significant (p = 0.07) largely due to the paradoxical increase in fasting triglyceride levels that occurred in some patients due to fish oil administration. The incremental intra-arterial infusions of acetylcholine produced no changes in systemic blood pressure, heart rate or altered forearm blood flow in the noninfused arm in the diabetic subjects at baseline or after either intervention.
Figure i summarises the mean changes in forearm blood flow in response to the intra-arterial infusion of acetylcholine in the diabetic subjects during the baseline study and after 6 weeks olive oil and fish oil administration. The infusions of acetylcholine increased forearm blood flow from basal values during each separate study, although the magnitude of change after fish oil administration was significantly greater for each dose of acetylcholine infused when compared to changes recorded during the baseline study and after olive oil administration (p < 0.01 for each dose). The mean increase in forearm blood flow for the four doses of acetylchofine with fish oil was 5.3 (CI: 4.0 to 7" g- 6.6) ml-100 ml 1.min -1. This compared with a mean increase in forearm blood flow during the baseline study of 2.5 (CI: 1.3 to 3.7) ml-100 ml-l.min -1 and after olive oil supplementation of 2.2 (CI: 1.1 to 3.3) ml. 100 ml-1. min-:. No differences were found between the mean increases in forearm blood flow to acetylcholine during the baseline study and after olive oil therapy. Figure 2 illustrates the changes in forearm blood flow to the acetylcholine infusions in the diabetic subjects after dietary fish oil supplementation. Initially the four doses of acetylchotine were administered to produce the maximal stimulated flow to this agent and the natural decline in flow was recorded until basal conditions were re-estabfished. The four doses of acetylcholine were then reinfused to give reproducible vasodilation. L-NMMA at a dose of 2 gmol/min was then infused for 5 min to inhibit that component of the increased blood flow to acetylcholine attributable to NO release from the endothelium. L-NMMA produced an immediate decline in blood flow and this change in forearm blood flow differed significantly from the natural decline in flow recorded after the initial acetylchofine infusions when compared at the same time points (p < 0.01).
L-NMMA was infused in each diabetic subject during the baseline studies and after fish oil and olive oil administration at 2 gmol/min for 5 min to assess the effect of the arginine analogue on basal blood flow (Table 3) . At this dosage, a modest reduction in basal blood flow occurred in the diabetic subjects when ingesting the fish oil supplements. This trend just failed to reach statistical significance when compared with the responses recorded at baseline and after olive oil supplementation (overall MANOVA p = 0.08). No differences in the responses to the incremental infusions of glyceryl trinitrate were found with either intervention when compared to changes at baseline. The mean increase in forearm blood flow recorded during the baseline study was 0.6 (CI: 0.3 to 0.9)ml.100mt-l.min 1 and after olive oil and fish oil were 0.7 (CI: 0.2 to 1.2) ml. 100 m1-1 .min -1 and 0.8 (CI: 0.4 to 1.2) ml. 100 m1-1-min -* respectively.
Discussion
Dietary supplementation with fish oil markedly improved endothelium-dependent vasodilation to acetylcholine Prior studies have shown that omega-3 fatty acids improve stimulated NO release from atherosclerotic endothelium in response to various pharmacological agents [11] . The mechanisms involved remain obscure but may relate to changes in receptor-effector coupling or to alterations in cell membrane fluidity [12] . We employed acetylcholine to stimulate NO release and L-NMMA, a stereospecific inhibitor of NO production or release, to assess endothelium-dependent vascular responses [16] . Forearm vasodilation to acetylcholine may also be influenced through inhibition of noradrenaline release from sympathetic nerve endings or by stimulating vascular Table 3 . Change in forearm blood flow after i and 5 min to the intrabrachial infusion of Na-monomethyl-L-arginine at baseline and after 6 weeks fish oil and olive oil supplementation prostacyclin production. However, prior studies in patients with hypertension [17, 18] suggest that changes in catecholamine release or increases in vasodilating prostaglandins to the intra-brachial infusion of acetylcholine play little part in influencing forearm blood flow. We cannot exclude a possible contribution of vasodilator prostaglandins in improving the forearm blood flow responses to acetylcholine in this study as prostanoid metabolism was influenced by the prescription of the fish oil supplements to the diabetic subjects. Our data lend support to increased receptor stimulated release of NO as an important component of the improved vasodilator response in diabetic patients ingesting fish oils. The increased relaxation to infused acetylcholine coupled with the marked decline in stimulated forearm blood flow to acetylcholine produced by L-NMMA, compared with the uninhibited decline in flow to the acetylcholine infusions, is consistent with enhanced NO release augmenting the vasodilator responses associated with fish oil administration. A modest reduction in basal blood flow was observed after the intra-brachial infusion of L-NMMA in the diabetic patients during fish oil supplementation that was not observed during the baseline study or after olive oil administration. This may indicate enhanced basal release of NO by the endothelium although this trend just failed to reach significance at the dose of L-NMMA infused and with the dose of fish oil prescribed.
In addition to promoting receptor-mediated vasodilation fish oils may alter vascular reactivity through a direct effect on smooth muscle cells or indirectly by altering the production of substances by other cells that affect endothelial cell function. Omega-3 fatty acids can inhibit leucocyte/endothelium interactions [19] possibly resulting in fewer reactive oxygen species that can inactivate NO [8, 20] . By inhibiting the release of platelet and endotheliumderived vasoconstrictor factors, fish oil therapy could augment vascular relaxations and favour a more vasodilated state. Finally, it has been suggested that omega-3 fatty acids influence the sensitivity of vascular smooth muscle cells promoting improved relaxations to pharmacological agents [11, 21] . With the doses of fish oils prescribed in this study, no differences were found in the dose-response curves to glyceryl trinitrate when baseline responses were compared with responses recorded after fish oil and olive oil interventions. These findings appear to exclude a non-specific change in vascular smooth muscle sensitivity as being responsible for the improved relaxations to acetylcholine recorded after fish oil administration.
Impaired vasodilator responses to acetylcholine and glyceryl trinitrate have been described in experimental models of diabetes [22] . We have previously reported impaired forearm vasodilator responses to the intra-brachial infusion of these agents in patients with Type 2 diabetes compared with a group of age-and sex-matched control subjects [15] . Fish oil therapy improved forearm vasodilator responses in diabetic subjects so that the dose-response curves to the acetylcholine infusions overlapped those previously recorded in healthy control subjects, without influencing the impaired responses to glyceryl trinitrate. These data may provide indirect evidence for impaired biotransformation of glyceryl trinitrate to NO in the diabetic patients. NO whether produced in the endothelium by the action of acetylcholine on muscarinic receptors, or after the biotransformation of glyceryl trinitrate in the smooth muscle cell, combines with guanylate cyclase in vascular smooth muscle to stimulate cyclic GMP and produce ultimate vasodilation [23] . The biotransformation of glyceryl trinitrate to NO requires the presence of intracellular sulphydryl groups. Depletion or oxidation of intracellular sulphydryl groups in vascular smooth muscle would impair the biotransformation process and render the vasculature tolerant to the drug [24] , without however altering the sensitivity to endogenously produced NO [25, 26] . It is recognised that cellular levels of sulphydryl donors and serum levels of primary antioxidants are decreased in diabetes [27, 28] . Thus, the increased oxidative stress associated with diabetes may promote oxidation or depletion of intracellular sulphydryl donors in diabetic subjects and impair the vasodilator responses to glyceryl trinitrate, without altering the smooth muscle response to endothelium-derived NO.
Deleterious effects on glucose and fatty acid regulation have been reported in diabetic patients ingesting fish oils [4, 29] . We observed a minor increase in fasting glucose levels with no change in total cholesterol and a non-significant decrease in fasting triglyceride levels to fish oil administrafon in this short-term study. These results further emphasize that the vascular effects of omega-3 fatty acids can be dissociated from their lipid lowering actions. Chronic endothelial injury associated with diabetes facilitates platelet aggregation and the release of platelet products that may cause vasospasm and thrombosis. Fish oils may curtail these events not only through a direct effect on platelets but also by augmenting the release of endothelium-derived NO and possibly vasodilator prostaglandins [30] . As impaired NO release from the endothelium has been implicated in the very earliest steps of atherogenesis [31] , omega-3 fatty acids could potentially retard a process in diabetic subjects that does not appear to be influenced by interventions that have concentrated on improving blood glucose control alone.
If a single dietary change could provide long-term protection from the micro-and macrovascular complications associated with diabetes, it would have considerable therapeutic potential. While the results of this study are encouraging, long-term trials under defined conditions of metabolic control and diet are required to confirm the safety and efficacy of fish oil administration before they can be recommended as an adjunct to traditional diabetic therapy.
